DSG3, His, Mouse
DSG3, His, Mouse

The purity of DSG3, His, Mouse is greater than 90% as determined by SEC-HPLC.

DSG3, His, Mouse

DSG3, His, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

DSG3, His, Mouse

To identify genes that could potentially serve as molecular therapeutic markers for human head and neck cancer (HNC),DSG3 is identified overexpressed in HNC, with the degree of overexpression associated with clinicopathologic features of the tumor. Inhibition of DSG3 significantly suppresses carcinogenic potential in cellular and in vivo animal studies. DSG3 is a potential molecular target in the development of adjuvant therapy for HNC.
Z06091
¥63,425.00

Ask us a question
Product Introduction
Species Mouse
Protein Construction
DSG3 (Glu50-Pro617)_x000D_
Accession # O35902-1		 His
N-term C-term
Purity > 95% as determined by Bis­Tris PAGE 
> 90% as determined by HPLC
Endotoxin Level Less than 1EU per μg by the LAL method.
Expression System HEK293
Theoretical Molecular Weight 64.3 kDa
Apparent Molecular Weight Due to glycosylation, the protein migrates to 70-75 kDa based on Bis-Tris PAGE result.
Formulation Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).
Reconstitution Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage & Stability Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples
  • DSG3, His, Mouse
    • DSG3, His, Mouse

    The purity of DSG3, His, Mouse is greater than 90% as determined by SEC-HPLC.

  • DSG3, His, Mouse
    • DSG3, His, Mouse

    DSG3, His, Mouse on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.


Background
Target Background To identify genes that could potentially serve as molecular therapeutic markers for human head and neck cancer (HNC),DSG3 is identified overexpressed in HNC, with the degree of overexpression associated with clinicopathologic features of the tumor. Inhibition of DSG3 significantly suppresses carcinogenic potential in cellular and in vivo animal studies. DSG3 is a potential molecular target in the development of adjuvant therapy for HNC.
Synonyms Desmoglein-3; PVA; CDHF6; SG3; DSG3; DSG-3

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.